Your session is about to expire
← Back to Search
PET/CT Imaging Agent for COVID-19
Phase < 1
Waitlist Available
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosed with SARS CoV2
Able to remain motionless for up to 30-60 minutes per scan.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Study Summary
This trial is studying a PET/CT imaging agent to see if it can help in finding and measuring damage caused by SARS CoV2 infection.
Who is the study for?
This trial is for men and women over 18 who had COVID-19 but are now negative, with no prior lung diseases. They must have had a lung image taken during their infection and be able to stay still for up to an hour per scan. It's not for those with other respiratory infections, pregnant or breastfeeding women, patients too heavy for PET/CT scans (>350lbs), or anyone unlikely to attend follow-up sessions.Check my eligibility
What is being tested?
The study tests a new imaging agent called 18F-αvβ6-binding-peptide in PET/CT scans on patients who've recovered from COVID-19. The goal is to see how well this peptide works in detecting changes in the lungs after SARS-CoV-2 infection.See study design
What are the potential side effects?
Potential side effects of the imaging agent used in this trial are not detailed here; however, common side effects from similar agents may include allergic reactions, injection site pain, or temporary discomfort during scanning.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with COVID-19.
Select...
I can stay still for up to an hour.
Select...
I had no lung conditions before my COVID-19 infection.
Select...
I have had two COVID negative tests before each scan.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Administration of 18F-αvβ6-BP
Secondary outcome measures
Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage
Other outcome measures
Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 18F-αvβ6-BPExperimental Treatment1 Intervention
Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.
Find a Location
Who is running the clinical trial?
University of California, DavisLead Sponsor
910 Previous Clinical Trials
4,706,981 Total Patients Enrolled
7 Trials studying COVID-19
7,283 Patients Enrolled for COVID-19
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You had a chest X-ray or CT scan while being diagnosed with an infection.I do not have any active infections in my lungs.I have been diagnosed with COVID-19.I can stay still for up to an hour.You are expected to live for less than 3 months.I am not pregnant or breast-feeding.I weigh more than 350lbs and cannot have a PET/CT scan.I had no lung conditions before my COVID-19 infection.I have had two COVID negative tests before each scan.I have been re-infected with COVID-19 between scans.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: 18F-αvβ6-BP
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment open for this clinical trial at the present time?
"Unfortunately, this clinical trial is not presently enrolling any subjects according to the information posted on clinicaltrials.gov. Initially published on May 1st 2020 and last updated September 1st 2022, this study has been closed for recruitment. Nonetheless, 1738 other trials are actively seeking patients at present."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger